Screening for von Hippel-Lindau disease by DNA polymorphism analysis

Area of Science:

• Genetics
• Oncology
• Hereditary diseases

Background:

• Von Hippel-Lindau (VHL) disease is a rare, inherited disorder causing multiple tumors.
• Currently, no biochemical test differentiates VHL gene carriers from non-carriers.
• Early identification of carriers is crucial for managing VHL disease.

Purpose of the Study:

• To evaluate DNA polymorphism analysis for identifying carriers of the VHL disease gene.
• To compare DNA analysis results with clinical screening in at-risk individuals.

Main Methods:

• Prospective comparison of DNA polymorphism analysis and clinical screening.
• Collected blood samples from 182 members of 16 VHL disease families.
• Assessed 48 at-risk asymptomatic individuals for occult disease and VHL gene carrier status.

Main Results:

• DNA analysis identified 9 likely VHL gene carriers and 33 non-carriers among 48 at-risk individuals (6 results were uninformative).
• All 9 predicted carriers showed evidence of occult VHL disease on clinical examination.
• 32 of 33 predicted non-carriers showed no clinical signs of VHL disease.

Conclusions:

• DNA polymorphism analysis is effective in identifying individuals likely to carry the VHL disease gene.
• This genetic testing method aids in focusing medical surveillance on high-risk individuals.
• Early identification may reduce morbidity and mortality associated with VHL disease.